After the Final Visit: How to Audit Claims of Lasting Psilocybin Benefit

“Benefits lasted a year” sounds like a simple conclusion. In practice, it can describe several different findings: improvement at the final visit, uninterrupted improvement across all visits, or a group average that remained lower than baseline despite individual relapses. These possibilities have different implications. Long-term research is valuable precisely because it can uncover those distinctions rather than compressing them into a durability slogan.

This article provides an audit trail for follow-up claims, not a prediction of how long any individual will improve. For basic outcome terminology, see the site's guide to response, remission, and relapse. Here the focus is on who was measured over time, what happened between visits, and what comparison remained available.

Identify when the clock starts

Follow-up may be measured from randomization, the first treatment session, or the final session. In a study involving more than one session, those are not the same date. A delayed-treatment design adds another complication because participants start treatment at different times. Before quoting a duration, identify the event that defines month zero and whether every participant follows the same schedule.

Gukasyan and colleagues reported a prospective 12-month follow-up of a depression study using immediate and delayed treatment groups. Twenty-seven people enrolled, and 24 completed both psilocybin sessions and were followed through 12 months after the second session. All 24 attended the follow-up visits. That strong retention among treatment completers is informative, but it should be distinguished from following every initially enrolled person through an identical intervention course. [1]

Ask whether a comparator still exists

A waiting-list comparison can help evaluate short-term differences before the delayed group receives treatment. Once both groups have received the intervention, the later assessment is no longer a comparison with an untreated randomized group. It can document persistence, recurrence, and subsequent care, but it cannot independently establish the counterfactual course without treatment.

This is why a large change from baseline at 12 months should not be presented as a 12-month placebo-controlled effect. Symptoms might also change with time, other treatment, life events, or regression toward a person's usual level. Those possibilities do not make observed improvement meaningless. They change the strength and type of causal claim that the follow-up can support.

Keep the denominator visible

A percentage is incomplete without knowing who was counted. Gukasyan and colleagues reported 75% response and 58% remission at 12 months among the 24 participants followed after completing treatment. Those figures describe that specific small cohort and its outcome definitions. They are not estimates of what every person with depression should expect from any psilocybin service. [1]

In other studies, people may die, withdraw, become unreachable, or decline questionnaires. These events should not be collapsed into a generic “lost to follow-up” category if more specific information is available. A result based on respondents alone can look more favorable when people doing poorly are less likely to respond. Sometimes the reverse can happen, making reasons for nonparticipation particularly important.

Long cancer follow-up requires special care

Agin-Liebes and colleagues followed participants from a cancer-distress trial at average intervals of 3.2 and 4.5 years after psilocybin administration. All 16 surviving participants were contacted, and 15 agreed to participate. The study reported continuing improvements and positive attributions to the therapy experience. Its authors also explicitly limited efficacy conclusions because of the parent crossover design and follow-up limitations. [2]

This is not a four-and-a-half-year randomized comparison of psilocybin against placebo. It is a valuable within-person follow-up among surviving participants. The distinction matters especially when illness itself affects who remains available for research. Reports of meaning and symptom relief should be described with their actual denominator and design rather than generalized to every member of the original sample.

Record everything that happened between visits

Subsequent antidepressants, psychotherapy, additional experimental treatment, and major life events can influence later outcomes. If a study allows usual care, that may be ethically appropriate and clinically realistic. But a later symptom score then reflects a treatment history, not necessarily the isolated effect of the original intervention. Readers should look for what was collected and how completely it was reported.

A follow-up report can acknowledge additional care without dismissing the original intervention. The correct question might be whether a supported psilocybin course is associated with better outcomes within a later care pathway. That is different from claiming one exposure was solely responsible for every improvement over the following year. The site's medication oversight discussion also explains why research participation should not prompt independent medication changes.

One endpoint does not reveal the whole trajectory

A participant can improve, relapse, receive additional treatment, and improve again before a final visit. Another can remain consistently well. If both have similar final scores, an endpoint-only summary may conceal important differences. Repeated observations, relapse definitions, and time-to-event analyses can help, although each requires clear methods and sufficiently complete data.

Likewise, a stable group average may hide substantial individual variability. Some participants may improve while others worsen, leaving the mean unchanged. Whenever possible, inspect individual trajectories or distributions alongside average scores. A claim of uninterrupted remission requires evidence about continuity, not merely a low score at widely separated assessments.

A transparent durability statement

A useful summary names the cohort, timing, retention, outcome definition, later treatments, and presence or absence of a comparator. It might describe sustained group improvement among followed completers while noting that long-term causation remains uncertain. That qualified statement communicates more than a dramatic duration alone. It preserves the encouraging observation while identifying exactly what a larger controlled study would need to establish.

Disclosure: It provides research education, not medical advice or a recommendation to use psilocybin.

Editorial disclosure: Generated pictures are illustrative, not study participants. Consult a qualified professional for personal care.